What is it about?
First paper to show that Palivizumab, a monoclonal antibody, is effective in ameliorating serious hospital acquired respiratory syncytial virus infections in a subset of neonates Without artificial intlelligence, it is extremely difficult to assess palivizumab for this population of patients. Study used real patient care data to show that a group of extremely low birth weight babies with or without congenital heart disease will stay less by 8 days on supplemental oxygen which can in turn reduce risk of chronic lung disease
Featured Image
Photo by Markus Winkler on Unsplash
Why is it important?
For the first time with this study we can safely recommend Palivizumab in the setting of hospital acquired RSV at least for a segment of high risk patients
Perspectives
This is a study that implement a very important tool in artificial intelligence to the medical and healthcare fields. Both the tool discipline and healthcare would benefit from this study. For the former, it gives an example of how artificial intelligence can be applied at the usual care level to better human health. For the latter, artigicial intelligence can solve many complex problems and questions that are impossible to comprehend without this powerful tool....simple statistics won't do the job
Dr Loai M Saadah
Global Medical Solutions & Zayed Military Hospital
Read the Original
This page is a summary of: Palivizumab Prophylaxis during Nosocomial Outbreaks of Respiratory Syncytial Virus in a Neonatal Intensive Care Unit: Predicting Effectiveness with an Artificial Neural Network Model, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, July 2013, Wiley,
DOI: 10.1002/phar.1333.
You can read the full text:
Resources
Contributors
The following have contributed to this page
